RayzeBio inc (DELISTED) (RYZB:DL)
62.49
0.00 (0.00%)
USD |
NASDAQ |
Mar 06, 16:00
RayzeBio Research and Development Expense (Quarterly): 18.17M for Sept. 30, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 18.17M |
| December 31, 2022 | 14.76M |
| Date | Value |
|---|---|
| September 30, 2022 | 18.83M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
14.76M
Minimum
Dec 2022
18.83M
Maximum
Sep 2022
17.25M
Average
18.17M
Median
Sep 2023
Research and Development Expense (Quarterly) Benchmarks
| Bristol-Myers Squibb Co | 2.695B |
| Karuna Therapeutics Inc (DELISTED) | 82.19M |
| Ambrx Biopharma Inc (DELISTED) | 16.27M |
| Pfizer Inc | 2.493B |
| Mirati Therapeutics Inc (DELISTED) | 114.77M |